volume 24, issue 4, P817-835 2011
DOI: 10.3233/jad-2011-102136
View full text
|
|
Share
Valentina Echeverria, Ross Zeitlin, Sarah Burgess, Sagar Patel, Arghya Barman, Garima Thakur, Magorzota Mamcarz, Li Wang, David B. Sattelle, Daniel A. Kirschner, Takashi Mori, Roger M. Leblanc, Rajeev Prabhakar, Gary W. Arendash et al.

Abstract: Alzheimer's disease (AD) affects millions of people world-wide and new effective and safe therapies are needed. Cotinine, the main metabolite of nicotine, has a long half-life and does not have cardiovascular or addictive side effects in humans. We studied the effect of cotinine on amyloid-β (Aβ) aggregation as well as addressed its impact on working and reference memories. Cotinine reduced Aβ deposition, improved working and reference memories, and inhibited Aβ oligomerization in the brains of transgenic (Tg)…

expand abstract